share_log

Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25

Benzinga ·  Nov 13, 2023 12:06

Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and announces Price Target of $5.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment